Dermatologic Surgery, the official scientific journal of the American Society for Dermatologic Surgery (ASDS), has published a special issue dedicated to research and innovations in the use of neuromodulators (such as BOTOX, Dysport, Xeomin and Jeuveau).

“For this special issue, we identified practice areas that, although non-FDA–approved, were novel and would be educational to those physicians looking to expand their scope of practice,” said Drs. Carruthers and Matarasso. “We endeavored to find subjects that were diverse and meet the needs of a growing patient population. We included manuscripts on the basic science of botulinum toxin, anatomical considerations and potential adverse events. Certainly, any robust publication should have material that will challenge and pique the reader's curiosity, so we included topics such as combination therapy, toxins on the horizon, accessory proteins and the potential of reversing the effects of neuromodulators.”

“This Special Issue is intended to be a standalone mini textbook on the current state of the art of neuromodulators, bringing together many of the world's experts on botulinum toxins,” said Editor in Chief William P. Coleman, III, MD. “We have asked the various manufacturers of these products to support the Special Issue both financially and by contributing their best up-to-date science. As most of the companies that market toxins are represented here, we can expose the reader to many different viewpoints and controversies.

Read more at Globe Newswire >>